Inserm, UMR970, équipe labellisée Ligue Contre le Cancer, Paris-Cardiovascular Research Center, 75015 Paris, France; Faculté de médecine, PRES Sorbonne Paris-Cité, Paris-Descartes University, 75006 Paris, France.
Inserm, UMR970, équipe labellisée Ligue Contre le Cancer, Paris-Cardiovascular Research Center, 75015 Paris, France; Department of Nuclear Medicine, Pitié-Salpêtrière Hospital, Sorbonne University, 75013 Paris, France.
Ann Endocrinol (Paris). 2019 Jun;80(3):159-162. doi: 10.1016/j.ando.2019.04.003. Epub 2019 Apr 11.
Metastatic pheochromocytoma/paraganglioma (PPGL) represents a major clinical challenge due to limitations in accurate diagnostic tools and effective treatments. Currently, patients classified at high-risk by means of clinical, biochemical and genetic criteria, require a lifelong monitoring, while it remains difficult to determine the metastatic potential of PPGL only on the basis of histopathological features. Thus, tumor molecular markers that improve the risk stratification of these patients are needed. In the past few years, we have witnessed an unprecedented molecular characterization of PPGL, which led to the emergence of promising candidate biomarkers predictive of metastatic behavior. Here, we briefly discuss these breakthroughs and provide some insights for the prospective implementation of molecular markers of metastatic PPGL in the clinical setting in years to come.
转移性嗜铬细胞瘤/副神经节瘤（PPGL）是一个主要的临床挑战，因为缺乏准确的诊断工具和有效的治疗方法。目前，通过临床、生化和遗传标准分类为高危的患者需要终身监测，而仅仅根据组织病理学特征来确定 PPGL 的转移潜能仍然很困难。因此，需要肿瘤分子标志物来改善这些患者的风险分层。在过去的几年中，我们见证了 PPGL 的空前分子特征描述，这导致了有前途的转移性行为预测候选生物标志物的出现。在这里，我们简要讨论这些突破，并为未来几年在临床环境中应用转移性 PPGL 的分子标志物提供一些见解。
